Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Transaction Price: $52.40 per American Depositary Receipt (ADR).
- Transaction Type: Increase in interest via dividend re-investment.
- Dividend Date: October 11, 2007.
Material Changes
The filing reports an increase in the interest of Dr. R G Greig in Ordinary Share ADRs. The specific quantity of shares acquired is listed as 48.30 (unit context unclear from text, likely thousands or a specific plan unit). No other material financial changes are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of a director's transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the exact number of ADRs acquired by Dr. R G Greig, as the text lists "48.30" without explicit unit clarification.
- Confirm the total dividend payout amount per share to validate the re-investment calculation.
- Check subsequent filings for broader financial performance data, as this 6-K is limited to director transaction reporting.